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ABSTRACT
Both the establishment of neuronal polarity and axonal growth are
crucial steps in the development of the nervous system. The local
translation ofmRNAs in the axon provides precise regulation of protein
expression, and is now known to participate in axon development,
pathfinding and synaptic formation and function.We have investigated
the role of miR-26a in early stage mouse primary cortical neuron
development. We show that micro-RNA-26a-5p (miR-26a) is highly
expressed in neuronal cultures, and regulates both neuronal polarity
and axon growth. Using compartmentalised microfluidic neuronal
cultures, we identified a local role for miR-26a in the axon, where the
repression of local synthesis of GSK3β controls axon development
and growth. Removal of this repression in the axon triggers local
translation of GSK3β protein and subsequent transport to the soma,
where it can impact axonal growth. These results demonstrate how the
axonal miR-26a can regulate local protein translation in the axon to
facilitate retrograde communication to the soma and amplify neuronal
responses, in a mechanism that influences axon development.
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INTRODUCTION
The morphological polarisation of pyramidal neurons through the
development of multiple dendrites and a long axonal projection is
one of the most complex structural and functional challenges faced
by any cell type. The mechanisms, both cellular and molecular,
that control this process have been extensively investigated, leading
to the identification of many important intracellular signalling
pathways and molecules, including phosphoinositide 3-kinase
(PI3K), Ras homologous (Rho)-GTPase, Par3/6, mammalian
target of rapamycin (mTOR) and protein kinase A (PKA)
(Arimura and Kaibuchi, 2007; Barnes and Polleux, 2009; Hapak
et al., 2018). Among these, glycogen synthase kinase 3β (GSK3β)
has been positioned at a signalling crossroads where it coordinates
the complex emergence of axon/dendrite morphology in neurons
(Kim and Snider, 2011).
GSK3 proteins are serine/threonine kinases that have been
described as key regulators across multiple neurodevelopmental
processes, from neurogenesis, neuronal migration and neuronal
polarisation, to axon growth and guidance (Hur and Zhou, 2010;
Kim and Snider, 2011). This broad regulatory capacity of GSK3
proteins can be explained by its long list of functional substrates,
including transcription factors such as cyclic AMP response
element-binding protein (CREB), neurogenin 2, Smad1, Jun and
β-catenin (Hur and Zhou, 2010). Moreover, the targeting of
transcription factors is complemented by the ability of GSK3 to
control the activity of several microtubule-associated proteins, such
as Map1b and Tau (Kim and Snider, 2011; Kim et al., 2006; Zhou
and Snider, 2005). For example, moderate inactivation of GSK3 at
the growth cone can promote microtubule stability, which is
necessary for efficient axon regeneration (Hur et al., 2011).
Unlike many other kinases, GSK3 proteins are normally active in
resting cells, with several regulatory mechanisms controlling their
activity, including protein-protein interactions, spatial regulation
and phosphorylation (Etienne-Manneville and Hall, 2003; Hengst
et al., 2009; Thornton et al., 2008; Wu et al., 2009). The constitutive
activity, together with the complex array of post-translational
mechanisms that can control substrate specific actions (Beurel et al.,
2015), suggest the need for tight regulatory mechanisms that can
control GSK3 levels. Despite this, the protein levels of GSK3β
during the establishment of neuronal polarity do not appear to
increase after inhibition of the proteasome, suggesting a lack of
proteasome regulation (Yan et al., 2006) and highlighting the
potential need and importance of GSK3β translation regulation.
Local translation of mRNAs in the axon allows the precise
temporal and spatial regulation of protein expression (Cioni et al.,
2018; Costa and Willis, 2018). Rather than just a distinctive
characteristic of developmental processes, axonal protein synthesis
is now considered an integral part of the biology of a neuron,
participating in processes needed for development, growth,
pathfinding, and formation and maintenance of pre-synaptic
terminals (Batista et al., 2017; Campbell and Holt, 2001;
Deglincerti et al., 2015; Gracias et al., 2014; Hengst et al., 2009;
Hengst and Jaffrey, 2007; Jung et al., 2012; Piper et al., 2006; Sasaki
et al., 2010; Yao et al., 2006).
In addition to the control of protein content in the axon
compartment, local protein synthesis offers the possibility of
communication from the axon to the neuronal soma (Batista and
Hengst, 2016). In effect, neurotrophins have been shown to signal
retrogradely in peripheral neurons after triggering the local
translation of specific effectors and/or transcription factors (Cox
et al., 2008; Ji and Jaffrey, 2012; Willis et al., 2007). In injury
models of the peripheral nervous system, local translation of
importin β1 and α3, together with RanBP1 are used in the retrograde
signalling complex that delivers the injury signal to the soma (Hanz
et al., 2003; Yudin et al., 2008). Recently, a similar mechanism of
information transmission was observed for hippocampal neurons,
where an axonal insult by Aβ1-42 triggered the local translation of
sentinel mRNAs encoding components of a retrograde signalling
complex that modulate the soma response to Aβ1-42 (Walker et al.,
2018). Although ‘axon to soma’ retrograde signalling after localReceived 11 May 2019; Accepted 19 December 2019
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translation has been described in response to injury insults, evidence
of its occurrence in developing axons, particularly in the CNS,
is absent.
The mRNA transcripts that are transported along the axon are
highly heterogeneous, being sensitive to both developmental cues
and pathophysiological conditions (Costa and Willis, 2018), which
has prompted the investigation of novel regulatory mechanisms
(Jung et al., 2012). Among those described so far, miRNAs have
emerged as important players in multiple cellular processes, such
as neurogenesis, axon development, pathfinding and neuron
connectivity (Bellon et al., 2017; Dajas-Bailador et al., 2012;
Hancock et al., 2014; Kaplan et al., 2013; Reh and Hindges, 2018).
Despite this growing number of studies demonstrating the
importance of miRNAs in axon and synapse development
(Rajman and Schratt, 2017; Swanger and Bassell, 2011), evidence
for their role in axon specification and neuronal polarisation has
been largely missing. Only recently, miR-338, which was
previously reported to control axonal outgrowth in cortical and
superior cervical ganglion neurons (Aschrafi et al., 2008; Kos et al.,
2017b), was shown to modulate cortical neuron migration and to
have an effect in neuronal morphology and polarity in vivo (Kos
et al., 2017a). Furthermore, a recent paper by Ambrozkiewicz et al.
(2018) demonstrated the capacity of miR-140 to act synergistically
with its host gene E3 ubiquitin ligase WW-containing protein 2
(Wwp2) andWwp1 in the establishment of axon-dendrite polarity of
developing cortical neurons in vivo.
Among the many miRNAs known to participate in neuron
development, the miR-26 family (miR-26a-1, miR-26a-2 and miR-
26b) have a known role in tissue growth and differentiation, with
regulated expression during development and tumorigenesis (Gao
and Liu, 2011). In the nervous system, miR-26a is highly expressed
in the mouse cerebral cortex at embryonic day 12 and throughout
cortical development, where it has been shown to regulate neural
progenitor differentiation and cell-cycle progression (Lambert et al.,
2018; Zhang et al., 2018). Beyond this role in differentiation, the
knocking down of miR-26a in peripheral sensory neurons led to
impaired axon regeneration (Jiang et al., 2015). In a brief report that
uncommonly used rat neonatal cortical neuron cultures for neurite
growth assays, inhibition of miR-26a showed an effect in neuritic/
dendritic growth, via the targeting of phosphatase and tensin
homologue (PTEN) (Li and Sun, 2013).
Considering that both GSK3β and PTEN are involved in pathways
that control neuron polarisation processes, we decided to investigate
the role of miR-26a in axon specification and polarity using mouse
primary cortical neurons, a model that provides the molecular and
cellular accessibility needed to dissect these processes.We show that
miR-26a is highly expressed during the development of primary
cortical cultures and regulates both axon specification and growth.
Importantly, the use of compartmentalised microfluidic chambers
allowed us to reveal a local role for miR-26a in the regulation of axon
development, in a process that requires the repression of local
synthesis of GSK3β in the axon. Removal of miR-26a-mediated
repression in the axon, triggers the local translation of GSK3β
protein and its subsequent transport to the neuronal soma, where its
activity can further regulate axonal function.
RESULTS
miR-26a regulates neuron polarisation and axonal growth in
cortical primary neurons
To investigate the role of miR-26a in the development of CNS
neurons in vitro, we first evaluated its expression in mouse primary
cortical neuron cultures. We found miR-26a being expressed in
cortical neurons at 4 h post plating, with an early trend towards
decrease that stabilises in more developed cultures up to 9 days
in vitro (Fig. 1A). Levels of the miR-26a target Gsk3b showed the
opposite progression (Fig. 1B).
Inhibition of miR-26a generated a significant decrease in the
axonal length of cortical primary neurons, similar to findings in
peripheral sensory axons and neurites (Jiang et al., 2015; Li and
Sun, 2013). In our studies with cortical neurons, transfection was
carried out 4 h after plating, and their development was evaluated
72 h later (Fig. 1C). At this timepoint, inhibition of miR-26a
significantly decreased axonal length compared with non-targeting
control probes (Fig. 1D,E). However, a closer morphological
examination of the transfected primary cortical cultures also
revealed a significant reduction in the proportion of neurons with
a single-axon phenotype (i.e. those polarised with a distinct and
unique axon projection; Fig. 1F-H). Although the total length of
neurites in non-polarised neurons was significantly decreased
(Fig. 1I), in those neurons with a single differentiated axon, the
rest of the developing dendrites did not show any change in length
after inhibition of miR-26a (Fig. 1L).
To further investigate the potential role of miR-26a in neuron
polarisation, we carried out overexpression studies using a miR-26a
mimic. The rise in miR-26a levels in cortical neurons produced a
significant increase in axonal growth (Fig. 2A,B). Crucially,
transfection with the miR-26a mimic also induced an increase in
the number of neurons withmultiple axon-like processes (Fig. 2C,D),
identified by the presence of the axonal marker JIP-1 (Dajas-Bailador
et al., 2014, 2008; Deng et al., 2014; Fu and Holzbaur, 2013), and by
the more traditional axonal marker tau (Fig. S1C,D). This multi-polar
neuronal phenotype was accompanied by a general increase in the
length of all projections, which were ∼40% longer than the total
average length of all neurites in same stage control cultures (Fig. 2E).
Overall, these results demonstrate that, in addition to affecting axonal
growth in cortical neurons, miR-26a can influence neuronal polarity.
The capacity of miR-26a to modulate axon specification and
growth, two cellular processes that are intrinsically linked in early
stage neuron polarisation, made us speculate whether miR-26a could
retain the ability to control both neuronal polarity and growth at
different stages of neuron development in culture. To assess this, we
transfected cortical neurons at two further time-points (24 h and
DIV5) with either miR-26a inhibitor or mimic, and analysed the
ability to develop/maintain polarity 72 h later. When transfected at
24 h, inhibition of miR-26a still decreased both axonal growth and
the number of single-axon neurons (Fig. S2A-C). However, we found
no significant changes in the polarisation of cortical neurons when
the activity of miR-26a was inhibited at the later time point (DIV5).
Unlike the effect seen at 24 h, transfection of the miR-26a inhibitor
after 5 days of culture did not decrease the percentage of single-axon
neurons (Fig. S2D,E). More importantly, even the overexpression of
the microRNA at this later time point did not significantly increase
the number of neurons with multiple axons (Fig. S2F,G).
miR-26a regulates the expression levels of GSK3β protein in
primary cortical neurons
The search for a molecular mechanism that elucidates the capacity
of miR-26a to control both neuron polarity and axon outgrowth led
us to investigate PTEN and GSK3β, which, respectively, bear three
and two highly conserved miR-26a-binding site sequences in their
3′UTRs (Fig. S3A,B) and have been previously described as
functional targets of miR-26a (Cui et al., 2015; Jiang et al., 2015;
Li and Sun, 2013). Knockdown of GSK3β and the use of specific
inhibitors cause the formation of multiple axons (Gartner et al.,
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2006; Jiang et al., 2005). As depicted by Jiang et al. (2005), GSK3β
manipulations prevail over PTEN on neuronal polarity, indicating
that PTEN acts upstream of GSK3β in polarity formation. For this
reason, we decided to initially focus on the latter and test our
hypothesis of whether GSK3β is a functional target of miR-26a in
cortical primary neurons.
Taking advantage of the morphological polarisation of cortical
neurons in vitro, we investigated whether miR-26a can directly
regulate the expression levels of GSK3β protein in neuronal somas
and/or growth cones by quantitative immunostaining.Overexpression
of miR-26a decreased GSK3β levels in both the soma and axonal
growth cones (Fig. S4A-C). Inhibition of miR-26a raised the levels of
the GSK3β protein in both morphological regions, but only in those
neurons that had managed to develop a growing axon (Fig. S4D,E).
Instead, in those neurons that failed to develop an axon, addition of
miR-26a inhibitor did not increase GSK3β levels in the soma (data
not shown). The examination of GSK3β levels following inhibition
of miR-26a in culture conditions was previously reported after
electroporation of mouse sensory neurons, in a process that did not
address specific subcellular localisation (Jiang et al., 2015). Here,
analysis of global protein levels in primary cortical neurons using
western blotting did not show significant changes (data not shown),
likely reflecting a sub-optimal incorporation of the inhibitor and
mimic. To test this, we used the highly transfectable neuroblastoma
cell line neuro-2A (N2A) in experiments with overexpression and
inhibition of miR-26a, which demonstrated the expected decrease
and increase in GSK3β (Fig. S4F,G). At the subcellular level, our
immunofluorescence imaging studies in primary cortical neurons
demonstrate that the effect of miR-26a on GSK3β levels could be
specifically detected in the axon growth cones.
This is an important observation as it may suggest a local effect of
this microRNA in the axon compartment, as previously reported
with other microRNAs (Bellon et al., 2017; Dajas-Bailador et al.,
2012; Hancock et al., 2014; Zhang et al., 2015). The capacity for
miRNAs to regulate axon development, and to do so by localising to
the axon compartment is a relatively new area of investigation
(Bellon et al., 2017; Dajas-Bailador et al., 2012; Wang and Bao,
2017). To address whether this potential mechanism was relevant in
the effects observed for miR-26a, we first assessed the presence of
both miR-26a and Gsk3b mRNA in the axons of cortical primary
neurons. For this, we cultured neurons in compartmentalised
microfluidic chambers, which allow the morphological and
functional separation of axons from somas (Taylor et al., 2005).
Both miR-26a and Gsk3b mRNA are detected in axonal RNA by
RT-qPCR (see Materials and Methods; Poulopoulos et al., 2019).
GSK3βmediates the functional effects of miR-26a in neuron
polarisation and growth
Considering the capacity of miR-26a to control GSK3β protein
levels in primary cortical neurons, we evaluated its role in functional
rescue experiments. For this, we employed two experimental
approaches. One was the use of a pharmacological inhibitor of
GSK3 activity (SB415286), which has been extensively used in the
past (Coghlan et al., 2000; Gobrecht et al., 2014; Guo et al., 2017;
Kim et al., 2006; Yoshimura et al., 2005). In our cultures, inhibition
of GSK3 activity increased both axonal length and the percentage of
single-axon neurons (Fig. S5A-C) (Jiang et al., 2005; Yoshimura
et al., 2005). The second approach was to use a GSK3β plasmid in
overexpression studies. As shown in Fig. S5D-F, transfection of
cortical neurons with pcDNA-GSK3β decreased axonal length
and the percentage of single-axon neurons. Overall, these two
experimental approaches confirmed the role of GSK3β in the
Fig. 1. miR-26a is expressed in primary cortical neurons and regulates
neuronal polarisation and axonal outgrowth. (A) Quantification of miR-26a
levels over development of cortical primary cultures from 4 h to 9 days in vitro.
Expression of miR-26a-5p was analysed by relative quantification using the
comparative Ct method (2−ΔΔCt) and the geometric mean of miR-100-5p,
miR-128-3p, miR-134-5p, miR-434-3p and let7a-5p was used as a reference;
data are mean±s.e.m. of five independent experiments. (B) Quantification of
Gsk3b expression levels over development of cortical primary cultures from 4 h
to 9 days in vitro. Expression of Gsk3b was analysed by relative quantification
using the comparative Ct method (2−ΔΔCt). The geometric mean of Gapdh and
Ube2was used as a reference; mean±s.e.m. of five independent experiments.
(C) Diagrammatic representation of the experimental design used in D-L.
(D) Representative images of polarised cortical neurons used for axon length
measurements after transfection with GFP plus a miR-26a inhibitor.
(E) Quantification of axon length after inhibition of miR-26a (50 nM miR-26a i),
showing up to a 25% decrease compared with a non-targeting control, n=5.
(F,G) Schematic representation and images of polarity changes induced by an
miR-26a inhibitor on cortical neurons. (H) Quantification of the number of
single-axon neurons after inhibition of miR-26a, expressed as a percentage of
neurons transfected with non-targeting control, n=5. (I) Quantification of the
length of all neurites from non-polarised neurons, n=5. (L) Quantification of
developing dendrites in single-axon neurons, n=5. Data are mean±s.e.m.;
one-way ANOVA with Bonferroni’s multiple comparison post-hoc tests (A,B).
Student’s t-test (E-L), **P≤0.01.
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specification and growth of axons in cortical neurons, and allowed
us to attempt functional rescue experiments after the inhibition and
overexpression of miR-26a. Pharmacological inhibition of GSK3
activity reversed the effect of the miR-26a inhibitor with regards to
neuronal polarity. For this, transfections were again performed at 4 h
after plating, with SB415286 (1 µM) being added 24 h after
transfections. Lack of GSK3 activity abolished the drop in 23%
of single-axon neurons after inhibition of miR-26a, returning to
those seen in control conditions (Fig. 3A,B). The effect of
pharmacological inhibition of GSK3 was not restricted to polarity;
it also reverted the decrease in axon length after inhibition of miR-
26a (Fig. 3C). Conversely, we found that overexpression of GSK3β
counterbalanced the increase in axon length after transfection with
miR-26a mimic (Fig. 3D-E). As the overexpression of PTEN also
compensated the rise in axon outgrowth after overexpression of
miR-26a (Fig. S5G-L), it was important to define the main effector
in our experimental model. For this, we designed target site blocker
oligos (GSK3β-TSB), which specifically prevent the capacity of
miR-26a to bind with GSK3β, without affecting other target
interactions, including PTEN. Addition of this GSK3β-TSB
produced both a decrease in axonal length and in the number of
single-axon neurons (Fig. 4A-E), similar to the effects seen with the
miR-26a inhibitor. Moreover, levels of GSK3β protein also
increased after incubation with the GSK3β-TSB (Fig. 4F,G).
Together, these results indicate that miR-26a can control neuronal
polarity and axon outgrowth through a mechanism that is mainly
dependent on GSK3β levels and activity.
Localised inhibition of miR-26a in the axon can regulate
axonal growth via GSK3β signalling
The use of primary cortical neurons in culture provides an
opportunity for the study of cellular mechanisms with great
Fig. 2. miR-26a overexpression induces axonal outgrowth and formation of multiple axon-like processes. (A) Diagrammatic representation of the
experimental design used in B-E and representative images of cortical neurons used for axon length measurements after transfection with GFP plus the miR-26a
mimic. (B) Quantification of axon length in single-axon neurons after overexpression of miR-26a (miR-26a m 20 nM), showing an increase in axon length
up to almost 40% compared with a non-targeting control, n=8. (C) Schematic representation and trace to demonstrate the polarity changes induced by the
miR-26a mimic, showing the increase in the number of neurons with multiple axons. Squares (I-IV) on the trace correspond to images from soma and neurite
terminals of cortical neuron. Arrows indicate JIP1 labelling, which was used as a marker of axonal growth cones. (D) Quantification of the number of neurons with
multiple axon-like processes after overexpression of miR-26a and expressed as a percentage of total neuron number transfected, n=5. (E) Quantification of the
overall length of all projecting neurites in multipolar neurons, n=5. Data are mean±s.e.m. Student’s t-test, **P≤0.01.
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spatiotemporal detail. It was thus important to determine whether
the capacity to control polarity and growth is achieved via changes
in GSK3β expression in specific subcellular domains.
For this, we used compartmentalised microfluidic chambers,
which allow the selective application of cell permeable miRNA
inhibitors, siRNA probes and/or drug treatments to either
compartment (Dajas-Bailador et al., 2012; Hengst et al., 2009;
Taylor et al., 2005; Zhang et al., 2015). Neurons were seeded in the
soma side and grown for 5-6 days in order to allow a significant
number of axons to cross into the axonal side of the device
(Fig. S6A). At this point, the cell-permeable inhibitor of miR-26a
was added to either the soma or axon compartment of the chambers.
The length of the axons was established from the site at which they
entered the axonal side of chambers up to the growth cone and
monitored for 48 h after application (Fig. S6A). As depicted in
Fig. S6B and Fig. 5A,B, axonal outgrowth is drastically reduced
when the miR-26a inhibitor is applied exclusively in the axonal
side of microfluidic chambers. Importantly, this effect on axonal
growth is not observed when the miR-26a inhibitor was added to the
soma side (Fig. S6C and Fig. 5C). The GSK3β-TSB for miR-26a
produced a similar outcome to that of the miR-26a inhibitor, both in
the axon and soma side (Fig. 5D-E). These data demonstrate that the
Fig. 3. GSK3β mediates the functional effects of miR-26a in neuron
polarisation and growth. (A) Diagrammatic representation of the
experimental design used in B and C. (B) Representative images and
quantification of the number of single-axon neurons after inhibition of miR-26a
and the addition of GSK3 inhibitor (SB415286, 1 µM) 24 h after transfections,
n=7. (C) Representative images and quantification of axon length after
inhibition of miR-26a and the addition of GSK3 inhibitor (SB415286, 1 µM) 24 h
after transfections, n=7. (D) Diagrammatic representation of the experimental
design used in E. (E) Representative images and quantification of axon length
after overexpression of both miR-26a and GSK3β, n=4. Data are mean±s.e.m.
one-way ANOVA with Bonferroni’s multiple comparison post-hoc tests,
*P<0.05, **P≤0.01.
Fig. 4. Block of GSK3β targeting by miR-26a recapitulates effects on
neuron polarisation and axon length. (A) Diagrammatic representation of
the experimental design used in B-G. (B) Representative images of neurons
after the addition of GSK3β-TSB oligos (GSK3β-TSB, 100 nM), n=5.
(C) Quantification of axon length after addition of GSK3β-TSB and respective
controls (TSB control, 100 nM), n=5. (D,E) Representative image and
quantification of single-axon neurons after addition of GSK3β-TSB, n=4.
(F,G) Representative images and quantification of GSK3β protein levels
expressed as a percentage of respective controls, n=4. Data are mean±s.e.m.
Student’s t-test, *P<0.05, **P≤0.01.
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effect on axonal growth requires a local mechanism triggered in the
developing axons of cortical neurons.
In this context, we reasoned that axonal application of the
inhibitor of GSK3 activity would rescue the locally mediated
decrease in axon growth induced by inhibition of miR-26a, which
should increase GSK3β expression. As predicted, addition of
SB415286 into the axonal compartment abolished the decrease in
axonal growth mediated by the miR-26a inhibitor (Fig. 5F-H).
However, unlike the experiments with miR-26a inhibitor alone,
which failed to affect axonal growth when applied to the soma, the
inhibition of GSK3 activity in the soma side also rescued the
decrease in axon length observed after axonal inhibition of miR-26a
function (Fig. 5I).
The observation that GSK3β activity in the soma is necessary to
prevent the effect of miR-26a inhibition on axon growth is in
agreement with previous findings in peripheral neuron regeneration
(Jiang et al., 2015). However, our results provide further mechanistic
insight and suggest that a local effect of miR-26a present in the
axon is required for the control of axon growth in cortical neurons.
These set of results put forward the interesting possibility that local
translation of GSK3β in the axon is a pre-requisite for function.
Newly synthesised GSK3β may then act on axon-dependent
mechanisms, likely impacting on cytoskeletal dynamics, but also
undergo retrograde transport towards the soma where it activates
further regulatory mechanisms controlling axonal growth. This
retrograde transport of locally synthesised proteins as a mechanism
Fig. 5. Local miR-26a effects in the axon
can regulate axonal growth via GSK3β
signalling. (A) Diagrammatic representation
of the experimental design used in B-E.
(B) Representative images and quantification
of axonal length after using a cell-permeable
inhibitor of miR-26a specifically applied to
the axon side of microfluidic chambers,
n=8. (C) Representative images and
quantification of axonal length after using a
cell-permeable inhibitor of miR-26a
specifically applied to the somal side of
microfluidic chambers, n=6.
(D) Representative images and quantification
of axonal length after using a cell-permeable
GSK3β-TSB (100 nM) specifically applied to
the axon side of microfluidic chambers, n=6.
(E) Representative images and quantification
of axonal length after using a cell-permeable
GSK3β-TSB specifically applied to the somal
side of microfluidic chambers, n=5.
(F) Diagrammatic representation of the
experimental design used in G-I.
(G) Representative images and (H)
quantification of axonal length after using
both miR-26a and GSK3 inhibitor
(SB415286, 1 µM) applied to the axonal
side of microfluidic chambers, n=8.
(I) Quantification of axonal length after
application of miR-26a in the axon side
and GSK3 inhibitor in the somal side of
microfluidic chambers, n=8. For all panels,
schematics of the microfluidic chambers
(upper right corner) depict where drugs were
added. Data are mean±s.e.m. Student’s
t-test (B-E), Kruskal–Wallis with Dunn’s
multiple comparison test (H), one-way
ANOVA with Bonferroni’s multiple
comparison post-hoc tests (I), *P<0.05,
**P≤0.01.
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of axonal signalling has been only demonstrated for a small number
of transcription factors (Cox et al., 2008; Ji and Jaffrey, 2012; Willis
et al., 2007), and very recently in a neurodegenerative CNS neuronal
model (Walker et al., 2018). However, this functional mechanism
had not been shown for intra-axonal miRNA-regulated translation.
Retrograde transport of locally translated GSK3β is required
for the regulation of axonal growthafter inhibition ofmiR-26a
in the axon
To test our hypothesis, we first evaluated the levels of GSK3β protein
in the axon and soma of cortical neurons after compartmentalised
application of the miR-26a inhibitor. Inhibition of miR-26a alone
in the axon compartment of microfluidic chambers produced a
significant increase in GSK3β protein levels, both in the axon
growth cone and soma of cortical neurons (Fig. 6A-C). Application
of the miR-26a inhibitor to only the soma side failed to produce an
increase in GSK3β protein, both in the soma and axonal growth
cones (Fig. 6D,E). As independent controls of the immunostaining
protocol, Fig. S7A-D data show the lack of change in βIII-tubulin
levels after both experimental conditions. Overall, these
findings support the idea that miR-26a can regulate GSK3β
levels in the axon, but to achieve its full functional effect, it
Fig. 6. Inhibition of miR-26a in the axon increases the expression levels of GSK3β protein in neuronal somas and axon growth cones. (A) Diagrammatic
representation of the experimental design used in B-E. (B,C) Representative images and quantification of GSK3β protein levels in the (B) growth cones and
(C) somas of cortical neurons after local application of cell-permeable miR-26a inhibitor in the axon side of microfluidic chambers, n=8. (D,E) Representative
images and quantification of GSK3β protein levels in the (D) growth cones and (E) somas of cortical neurons after local application of cell-permeable
miR-26a inhibitor in the somal side of microfluidic chambers, n=5. Data are mean±s.e.m. Student’s t-test, *P<0.05.
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requires an increase in GSK3β levels in the soma that is axon
dependent.
Direct demonstration that miR-26a regulates GSK3β translation
in the axons was obtained following the addition of the translation
blocker emetine (Villarin et al., 2016) in the axon compartment after
local inhibition of miR-26a. In this experiment, cortical axons were
treated with emetine 18 h after axonal application of miR-26a
inhibitor and imaged 6 h later. As seen in Fig. 7A-C, emetine
addition prevented the increase in GSK3β levels in both the axon
and soma of cortical neurons. This experiment confirms that
translation in the axon is needed for the observed increase in GSK3β
levels in both subcellular domains.
To further examine the validity of this novel mechanism, we
devised a compartmentalised culture model where overall axonal
transport is impaired, thus preventing effective retrograde signalling
of axonally synthesised GSK3β. For this, we used a microtubule-
destabilising drug, nocodazole, which has been previously
demonstrated to disrupt axonal transport (Gobrecht et al., 2014;
Saijilafu et al., 2013; Twelvetrees et al., 2016), an observation that
we further confirmed in our own experimental model using live
imaging of mitochondria (Movies 1 and 2). In this experiment,
addition of nocodazole significantly decreased the number of
moving mitochondria, while increasing those in static condition
(Fig. S8A).
Fig. 7. Inhibition of protein translation in the axon prevents the increase in GSK3β levels in both axon and soma subcellular compartments.
(A) Diagrammatic representation of the experimental design used in B and C. (B,C) Representative images and quantification of GSK3β protein levels in both
(B) growth cones and (C) somas of cortical neurons treated with translation inhibitor emetine (100 nM) 18 h after axonal application of miR-26a inhibitor and
imaged 6 h later. For all the panels, schematics of the microfluidic chambers (above the graphs) depict where drugs were added. Applications to the axon side are
illustrated in green, n=5. Data are mean±s.e.m.; one-way ANOVA with Bonferroni’s multiple comparison post-hoc tests, **P≤0.01.
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Following this corroboration of impairment of axonal transport,
cortical axons were treated with nocodazole 18 h after axonal
application of miR-26a inhibitor and imaged 6 h later. As shown in
Fig. 8A,B, addition of nocodazole after inhibition of miR-26a in the
axon still led to a significant increase in axonal GSK3β levels, but,
crucially, prevented the previously observed increase in the soma
(Fig. 8C). Overall, when these experiments are put together with our
local application of emetine and functional studies, they provide
demonstration of two key mechanisms. First, local synthesis of
GSK3β in the axon is regulated by axonal miR-26a, which is
normally repressing its translation. Second, regulation of axonal
growth by GSK3β after release of miR-26a repression requires
the transport of newly synthesised GSK3β to the somas of
cortical neurons.
DISCUSSION
The tight control of multiple signalling pathways allows the
development of axon/dendrite polarity in neurons and provides
the structural platform for the establishment of neuronal
communication in the nervous system (Barnes and Polleux, 2009;
Namba et al., 2015). Here, we demonstrate how a single microRNA
can modulate two distinct but also sequentially related cellular
Fig. 8. Retrograde transport of locally translated GSK3β after inhibition of miR-26a in the axon. (A) Diagrammatic representation of the experimental
design used in B and C. (B,C) Representative images and quantification of GSK3β protein levels in both (B) growth cones and (C) somas of cortical neurons
treated with nocodazole (100 nM) 18 h after axonal application of miR-26a inhibitor and imaged 6 h later. For all the panels, schematics of the microfluidic
chambers (above the graphs) depict where drugs were added. Applications to the axon side are illustrated in green, n=8. Data aremean±s.e.m.; one-way ANOVA
with Bonferroni’s multiple comparison post-hoc tests, **P≤0.01.
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processes, axon specification and growth, by controlling the axonal
translation of GSK3β. In primary cortical neurons, inhibition of
endogenous miR-26a leads to a remarkable process of long-distance
signalling, where both local axon translational of GSK3β and its
transport to the soma are required for the regulation of axon
development.
The capacity for miR-26a to regulate these neuronal processes
supports previous experimental evidence that axonal growth is not
just a consequence of axonal specification (Jiang et al., 2005). As
such, axon ablation to eliminate length differences can reset polarity
(Bradke and Dotti, 2000; Dotti and Banker, 1987), while promotion
of neurite growth can lead to axon specification (Lamoureux et al.,
2002; Nakamuta et al., 2011). Although axon specification versus
growth is the focus of active study, research has also shown that
several molecules, including GSK3β, can regulate both processes
(Arimura and Kaibuchi, 2007; Itoh et al., 2010; Jiang et al., 2005;
Kim and Snider, 2011; Lewis et al., 2013). The ability of GSK3β to
crosstalk with most of the pathways reported to control these
morphological mechanisms, at the transcription, translation and
cytoskeleton level, suggests that it may function as a central node in
the coordination and integration of neural development and
the establishment and maintenance of polarity (Beurel et al.,
2015; Guo et al., 2016; Hur and Zhou, 2010; Inoki et al., 2006; Kim
and Snider, 2011).
The role of GSK3β in axonal growth has been demonstrated both
at the developmental level (Hur and Zhou, 2010; Hur et al., 2011;
Kim et al., 2006) and in regenerative processes following axonal
injury (Diekmann and Fischer, 2015). In this regard, although the
control of axonal growth has been long recognised (Kim and Snider,
2011), its precise role in regeneration has been more controversial
(Leibinger et al., 2017), mainly due to the fact that a multitude of
regulatory pathways and targets can be involved in GSK3β activity.
In effect, the capacity of GSK to control such an array of cellular
functions may arise from the multiple sophisticated mechanisms
that regulate its action and protein expression, ensuring that it can
only phosphorylate substrates at a precise time and in discreet
subcellular compartments (Beurel et al., 2015).
As fundamental regulators of protein translation in the nervous
system (Davis et al., 2015), the investigation of miRNAs and their
specific role in the axon has rapidly expanded in recent years
(Kaplan et al., 2013; Wang et al., 2015; Zhang et al., 2015). Studies
from us and others (Bellon et al., 2017; Dajas-Bailador et al., 2012;
Sasaki et al., 2014) have shown how regulation of local translation
by specific miRNAs can control energy metabolism, growth and
branching of axons. For example, Kar et al. (2013), elegantly
showed how axonal transfection of miR-16 or a miR-16 inhibitor in
rat sympathetic neurons was able to regulate mRNA levels of two of
its targets (eIF2B2 and eIF4G2) in the axon, whereas no effect on
the levels in the soma of the neuron was observed. In CNS neurons,
miR-9-5p was shown to locally control axon development
by targeting the microtubule-associated protein Map1b (Dajas-
Bailador et al., 2012).
Here, we demonstrate that axonal miR-26a can modulate neuron
polarity and axon growth in primary cortical neurons via the
regulation of GSK3β protein levels. Inhibition of miR-26a led to a
decrease in neurons with single axonal projections, while its
overexpression promoted the generation of neurons with multiple
‘axon-like’ neurites. In a recent study, miR-338 was shown to have a
role in neuronal placement and polarisation in the cortical plate,
controlling neuronal polarity, migration and/or cortical placement
cues (Kos et al., 2017a). In the case of miR-26a, we show a cell-
autonomous role in the regulation of axon specification and growth of
CNS neurons, a function that was also recently described for miR-
140-3p (Ambrozkiewicz et al., 2018). In this study, miR-140-3p
translationally inhibits the expression of the Src family tyrosine
kinase Fyn to control laminar distribution and polarised morphology.
However, unlikemiR-140-3p, which serves to inhibit axon formation
in developing cortical neurons, endogenous miR-26a promotes axon
specification and growth in primary cortical neurons. In primary
cortical neurons, the levels of miR-26a showed a trend towards a
decrease from the time of plating, which stabilised towards later
stages of culture (DIV 9), when fast axonal growth starts to decline
and synaptic maturation begins (Chiappalone et al., 2006; Dotti et al.,
1988; Opitz et al., 2002). In vivo, levels of miR-26a have been
reported to increase from ∼E15 to P0 (Zhang et al., 2018), probably
reflecting the active growth of axons during this period of cortical
development (Lewis et al., 2013).
The unique ability of miR-26a to affect both polarisation and
axonal growth is mainly achieved via the targeting of GSK3β, which
is a known regulator of both processes. Additionally, the fact that
miR-26a can also target PTEN, an upstream member of the GSK3β
signalling pathway, reinforces its role as an important regulator of
axon development. Crucially, our study has also unravelled a
previously unknown mechanism for neuronal information
processing and GSK3β signalling in developing CNS neurons.
In effect, local inhibition of miR-26a in the axon produced a
significant increase in GSK3β protein levels and a decrease in
axonal growth. Although axonal inhibition of miR-26a increased
GSK3β protein levels in both the axon and soma of cortical neurons,
this was not observed when inhibition of this microRNA was
restricted to the soma side of compartmentalised microfluidic
chambers, indicating an axon-exclusive regulation of GSK3β
translation via miR-26a.
Functionally, GSK3β activity is needed in both soma and axon
compartments, as the decrease in axonal length observed after
inhibition of miR-26a in the axon was prevented by local application
of the inhibitor of GSK3 activity (SB415286) in either the soma or
axon side of microfluidic chambers. The GSK3β expression studies
reveal a molecular mechanism where local translation of GSK3β in
the axon is normally repressed by the presence of miR-26a, thus
allowing axonal development and growth. However, when miR-26a
function is inhibited in the axon, local translation of GSK3β is
triggered, followed by transport to the soma of cortical neurons.
Although the activity of GSK3β is required in the axon and soma, the
somatic increase in GSK activity that is capable of regulating axon
function is dependent on its translation in the axon compartment.
Confirmation of this mechanism was first provided by the inhibition
of local translation (emetine addition), which blocked the increase
in GSK3β levels in both axon and soma; and, second, by the
impairment of axonal transport (nocodazole application), which
prevented the increase in GSK3β protein levels that was observed in
the soma after axonal inhibition of miR-26a. Reassuringly,
nocodazole application did not stop the miR-26a inhibition-
dependent local translation of GSK3β in the axon, but the use of
dynein inhibitors (i.e. ciliobrevin; Walker et al., 2018) would be
needed to confirm the specific molecular mechanism involved in its
retrograde transport to the soma. Levels of GSK3β protein after the
concurrent inhibition of miR-26a in the axon and impairment of
axonal transport indicates that 6 h are sufficient to produce a
significant increase in GSK3β protein levels in the axon. This likely
reflects the high rate of GSK3β axon translation and transport
following release of miR-26a repression.
The lack of effect when a miR-26a inhibitor or GSK-TSB are
applied only in the soma suggests that the interaction of miR-26a
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with Gsk3b mRNA takes place exclusively in the axon
compartment, possibly reflecting independent transport of the
precursor miRNA, as recently shown by Corradi et al. (2018). In the
case of GSK3β, its activity was previously shown to regulate axon
regeneration in a coordinated way, acting at the growth cone to
control microtubule dynamics and in the neuronal soma to control
gene expression (Saijilafu et al., 2013). In follow-up studies, the
Zhou group (Jiang et al., 2015) proposed that miR-26a activity in
peripheral neurons was needed to maintain lower protein levels of
GSK3β and efficient axon regeneration, via a mechanism where
miR-26a did regulate GSK3β exclusively in the soma, upstream
of the regeneration-associated transcription factor Smad1. Our
findings in CNS developing neurons demonstrate a previously
unforeseen functional link, where actions of miR-26a in the axon
can control GSK3β levels and activity locally, but also be
retrogradely transported to impact on somatic regulatory
mechanisms that control axon development and growth. It is
possible to speculate that Smad1 might also be acting downstream
of miR-26a and GSK3β in the soma of CNS neurons, as
demonstrated by Jiang et al. (2015) in peripheral axons. Whether
the retrograde mechanism observed by us in cortical cultures is also
relevant in sensory neurons remains to be established.
In recent years, local protein synthesis has been confirmed as a
cellular process that can provide structural and regulatory
components that are specifically needed in the axon, either during
development, synaptic maturation or regeneration (Batista et al.,
2017; Batista and Hengst, 2016; Costa and Willis, 2018; Campbell
and Holt, 2001; Si et al., 2003; Verma et al., 2005; Yoon et al.,
2012). Among the least expected members of the axon translatome
are transcription factors (Cox et al., 2008; Ji and Jaffrey, 2012) such
as CREB, which can be retrogradely transported to the nucleus to
promote neuronal survival. In this way, local axon translation can
facilitate and amplify communication between the axon and the
neuronal soma, allowing the transport of newly synthesised axon
‘protein messengers’ (Cox et al., 2008). Although this mechanism
has been shown in peripheral neurons and after injury (Ben-Yaakov
et al., 2012; Terenzio et al., 2018; Walker et al., 2018), we show that
retrograde transport of a locally translated signalling molecule can
achieve a functional outcome in developing CNS neurons.
Additionally, our results demonstrate how a single miRNA can
use the spatiotemporal control of axonally originated protein
synthesis to impact events globally in the soma. This is a
significant observation that challenges the prevalent view of
miRNAs as only fine tuners of protein translation. In fact,
localised regulation by specific miRNAs can dramatically change
protein levels in defined neuronal compartments. The notable
finding is how these changes in the axon can be used to
communicate signalling information to the soma, in ways that can
influence axonal growth.
Our findings have placed miR-26a at a junction of regulatory
mechanisms that are able to impinge on neuronal polarity and axon
development via the control of GSK3β levels. In this context, the
relatively high levels of miR-26a expression in mature neuronal
cultures and CNS raises potentially relevant questions about its role
in adult brain. There is now a clear understanding of how the loss of
axon and neuron connectivity constitutes a fundamental step in the
early and progressive degradation of network information capacity
(Coleman, 2005; Conforti et al., 2007). Interestingly, both miR-26a,
as part of a signature group of miRNAs known to be deregulated in
Alzheimer’s disease (Cogswell et al., 2008; Leidinger et al., 2013),
and GSK3β, which has shown increased activity leading to tau
hyperphosphorylation in various Alzheimer’s disease models, have
been implicated in neurodegenerative processes (Dargahi et al.,
2015; Hooper et al., 2008). Future work will need to establish
whether the spatiotemporal control of GSK3β molecular
mechanisms that are regulated by axonal miR-26a in developing
neurons could also have an impact in neuronal function in the
mature and ageing brain.
MATERIALS AND METHODS
Primary cortical neuron cultures
Mice (C57/BL6) were housed and bred in compliance with the ethics and
animal welfare in accordance to the Animal (Scientific Procedures) Act
1986. C57/BL6 mouse embryos at E16.5 stage of development were
culled and their brains removed. Brain cortices were dissected, and the
meninges separated under a dissection microscope. The tissue was further
incubated in Hanks Balanced Salt Solution (HBSS, Ca2+ and Mg2+-free;
Gibco) with 1 mg/ml trypsin and 5 mg/ml DNAse I (Sigma-Aldrich) at
37°C for 30 min. Following the addition of 0.05% (v/v) soybean trypsin
inhibitor (Sigma-Aldrich), the tissue was mechanically dissociated in
Neurobasal media (Invitrogen) supplemented with 1× GlutaMax and 2%
B-27 (Gibco). Dissociated neurons were resuspended in supplemented
Neurobasal media (10×106 cells/ml). For functional assays and RNA
extraction, neurons were plated at a final seeding density of
1.75×105 cells/cm2 in six-well plates (Corning) with or without
22×22 mm glass coverslips (Menzel Glaser) previously coated with
50 µg/ml poly-L-ornithine (PLO; Sigma-Aldrich). For functional assays
with cell-permeable target site blockers (Table S1), neurons were plated at
a final density of 3.5×103 in 12-well plates (Corning) with PLO-coated
19 mm glass coverslips (Menzel Glaser). For experiments that required
over 7 days in culture, media was replenished with one quarter of its
volume every 2-3 days.
Depending on the experimental approach, neuronal transfections were
performed 4 h, 24 h or 5 days after plating using 5 µl/well of Lipofectamine
2000 reagent and 250 µl/well of Opti-MEM reduced-serum media (Thermo
Fisher Scientific), in accordance to manufacturer’s instructions. miRCURY
LNA (Locked Nucleic Acid) microRNA inhibitor (50 nM), inhibitor control
(50 nM), mimic (20 nM) and mimic control (20 nM) of miR-26a (all
Qiagen) were used for transfections. In all cases, 1 µg pmaxFP-Green
(Lonza) was co-transfected for visualisation of transfected neurons. For
protein overexpression studies, neurons were transfected with 1 µg pmaxFP-
Green (Lonza; hereafter referred to as GFP) and either 1 µg of empty vector
or 1 µg of pcDNA-GSK3β.
To rescue the effects of miR-26a inhibition, cortical neurons were
co-transfected with 1 µg GFP and LNA inhibitor control or LNA miR-26a
inhibitor (50 nM), while the GSK3 inhibitor SB415286 (Tocris) was used at
a concentration of 1 µM and added to the culture 24 h after plating.
Cell-permeable target site blockers (Table S1) GSKβ-TSB-1 (50 nM) and
GSKβ-TSB-2 (50 nM) (hereafter referred to together as GSKβ-TSB for
simplicity) or GSKβ-TSB-control (100 nM) were applied 24 h after plating
and incubated for 48 h.
In all experiments, cortical neurons were fixed in 4% paraformaldehyde
(Thermo Fisher Scientific) 72 h after transfection and washed in PBS before
direct visualisation and/or immunostaining. Microscope imaging was
carried out using a wide-field fluorescence microscope (Axiovert 200M,
Zeiss) coupled to a CCD camera (Photometrics CoolSnap MYO) and
Micro-Manager software 1.4.21 (Edelstein et al., 2010).
Neuro2A neuroblastoma cell line cultures
Neuro2a cells (ECACC; Accession Number 89121404) were maintained in
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) supplemented with
10% foetal calf serum and 1% penicillin-streptomycin (Sigma-Aldrich) and
seeded onto 12-well plates (Corning) at a density of 1.5×105 cells/well.
After 24 h, miR-26a inhibitor (100 nM), inhibitor control (100 nM), miR-
26a mimic (100 nM) and mimic control (100 nM) were transfected using a
1.5 µl/well of Lipofectamine 2000 reagent and a 200 µl/well of Opti-MEM.
Media were changed 24 h later and cells scraped into 100 μl of RIPA buffer
[50 mMTris-HCl (pH 8.0) with 150 mM sodium chloride, 1%NP-40, 0.5%
sodium deoxycholate and 0.1% sodium dodecyl sulfate; all Sigma-Aldrich]
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with protease inhibitor cocktail (1:100, Sigma-Aldrich) 48 h after
transfection. Samples were then lysed by snap freezing and centrifuged
for 20 min at 12,000 g to collect the supernatants.
Western blotting
Neuro2A protein extracts were run on a 12% SDS-PAGE gel, blotted onto a
45 µm nitrocellulose membrane (GE Healthcare) and blocked in 5%
skimmed milk in Tris-buffered saline 0.1% Tween (TBS-T; Sigma-Aldrich)
for 1 h at room temperature. Membranes were probed overnight with anti-
GSK3β and anti-GAPDH (Table S1) in 5% skimmed milk in 0.1% TBS-T
followed by a chemiluminescence protocol using HRP-conjugated rabbit
anti-mouse Ig (Dako; 1:3000). After a 1 min membrane incubation with
Western Lightning Plus ECL (Perkin Elmer), signal detection was
performed with Amersham Hyperfilm ECL (GE Healthcare) in a dark
chamber. Image analysis was conducted using the peak area method for
relative quantification in Fiji software and GSK3β signal was normalised to
the loading control (GAPDH). Data are expressed as relative density to
control of two independent experiments.
Compartmentalised neuronal culture in microfluidic chambers
Primary cortical neurons were cultured for 5 days in microfluidic devices
with 150 µm long microgrooves (SND150; Xona Microfluidics). The use
of these chambers allows the fluidic isolation and functional
compartmentalisation of the axon and somatodendritic compartments. For
simplicity the somatodendritic compartment is hereafter designated somal
channel throughout the text. The devices were prepared as described
previously (Garcez et al., 2016). Briefly, ethanol sterile devices were
mounted onto PLO-coated 35 mm culture dishes (Nunc, Thermo Fisher
Scientific) and both channels were equilibrated for 1 h with supplemented
Neurobasal media. Following collection of excess media from the devices’
reservoirs, cortical neurons were added onto the designated somatodendritic
compartment at a seeding density of 4×106 cells/ml and incubated for 30
min (37°C 5% CO2) to allow for cell attachment. The reservoirs of the
devices were then topped up with supplemented Neurobasal media and
incubated at 37°C in 5% CO2. Axons were allowed to extend and cross the
microgrooves to the axonal channel. Even after 8 days of culture, only
axonal projections have grown long enough to extend through microgrooves
into the opposite side of the channel. This is demonstrated by the fact that, at
this stage of culture, dendritic staining with MAP2 was restricted solely to
the somatodendritic compartment of microfluidic chambers (Fig. S8B).
Moreover, average dendritic length at this stage of culture in our
experimental model was 91.53±2.7 µm, significantly shorter than the
150 µm long microgrooves of the chambers.
Functional experiments were performed after 5-6 days in vitro. Cell-
permeable Power inhibitor miR-26a or Power inhibitor control at 100 nM
(all Qiagen) and cell-permeable GSK3β-TSB [GSKβ-TSB-1 (50 nM) plus
GSKβ-TSB-2 (50 nM)] or GSK3β-TSB-control at 100 nMwas added to the
axon side of the microfluidic device at day 5. As cell-permeable
oligonucleotides are incorporated by non-assisted uptake, higher oligo
concentrations are necessary due to the inherently less efficient uptake
kinetics. A difference in volume of ∼100 µl was maintained at all times
between the somal and axonal channels in order to maintain fluidic
isolation. Live imaging of the axons in the axonal channel was performed at
different time points (0, 24 and 48 h) after addition of inhibitors using an
Axiovert 200 M microscope (Zeiss) with a 10× phase contrast lens. When
required, the axons projecting into the axonal chamber were labelled with
either acetylated tubulin (Fig. 5) or βIII-tubulin (Figs 6–8). To rescue the
local effects of miR-26a inhibition, we added the GSK3 inhibitor SB415286
(1 µM) to the axonal channel, together with the cell-permeable inhibitor of
miR-26a-5p or inhibitor control at 100 nM. Live imaging of the axons in the
axonal channel was performed at 0 h and 24 h after addition of drugs/
inhibitors. To impair axonal transport, nocodazole (100 nM, Sigma-
Aldrich) was added 18 h after the addition of the cell-permeable miR-26a
inhibitor. To inhibit protein translation, emetine (100 nM, Sigma-Aldrich)
was added 18 h after the addition of cell-permeable miR-26a inhibitor.
Following 6 h of nocodazole or emetine incubation (24 h in total after
addition of miRNA inhibitors/controls), devices were removed, and neurons
fixed and immunolabelled for GSK3β protein and βIII-tubulin.
Mitochondrial motility
To test the capacity of nocodazole to disrupt axonal transport, neurons were
plated in PLO-coated 35 mm high µ-Dishes (Ibidi) at a seeding density of
3.5×103/ml cells, treated at day 5 with 100 nM nocodazole or DMSO for
6 h. MitoTracker Green FM (Invitrogen) was then incubated at 100 nM for
30 min at 37°C. Images of axons were acquired at 37°C on a Zeiss TIRF
microscope coupled with an EMCCD (Photometrics PVCam) camera using
ZEN 2010 software (Carl Zeiss), at the rate of 1 frame/s for 3 min. Videos of
15-25 random axon fields were acquired from three independent
experiments, and motile and static mitochondria were scored using Fiji
software. Data are expressed as a fraction of motile or static mitochondria
from total mitochondria (mean±s.e.m.).
DNA constructs and oligos
For the pcDNA-GSK3β and pcDNA-PTEN constructs, both Gsk3b and
Pten cDNAs were PCR amplified from a replication construct [pMD18-
TSimple (Sino Biological) and pCMV-Sport6, respectively (Source
Biosciences)], with primers containing the appropriate restriction sites
(Table S1, IDT). The amplicons were cloned into pcDNA3.1/Zeo(+) vector
(a kind gift from Dr Simon Dawson, University of Nottingham, UK), using
Nhe/XbaI (Gsk3b) and BamHI/XbaI (Pten) restriction sites. All miRNA
mimics, inhibitors, cell-permeable Power inhibitors, target site blockers
(GSK3β-TSB-1, GSK3β-TSB-2 and GSK3β-TSB-control) and miRNA
qPCR primers used in this study were obtained fromQiagen and are listed in
Table S1, together with mRNA qPCR primers.
RNA extraction
On six-well plates, cells were scraped into 250 µl/well of TRIzol Reagent
(Thermo Fisher Scientific). Axonal RNA was obtained as described
previously (Garcez et al., 2016) with a few modifications. Cortical neurons
were grown in microfluidic chambers for 8 days, when the average dendrite
length is ∼40% lower than the 150 µm microgrooves (91.53±2.78 µm) and
Map2 staining shows no crossover of dendritic projections into the axonal
side (Fig. S8B).
Cells were washed twice with PBS before addition of 20 µl of TRIzol to
each reservoir of the axonal channel and incubation for 2 min at room
temperature. A volume of 100 µl of PBS was kept in the soma reservoirs to
prevent contamination from opposite channel. Following collection of
axonal sample, the somatodentritic fraction was obtained in the same
manner. Fractions from 40-50 devices were collected for each independent
experiment. Total RNA was isolated following manufacturer’s instructions
and resuspended in RNAse-free water (Thermo Fisher Scientific) before
storage at −80°C.
RT-qPCR
FormiRNA expression studies, cDNAwas synthesised frommaturemiRNAs
using the miRCURY LNA Universal cDNA synthesis kit (Qiagen, UK)
according to the manufacturer’s instructions, using 10 ng of total RNA. For
each timepoint, five biological samples were run in duplicate using
miRCURY LNA primers (Table S1, Qiagen, UK). RT-qPCR was
undertaken using the ExiLENT SYBR Green master mix kit (Qiagen, UK).
For mRNA targets, cDNA was synthesised from 100 ng total RNA (five
biological replicates), using SuperScript IV and Oligo(dT)20 primer
(Invitrogen) according to the manufacturer’s instructions. qPCR was
undertaken using the PowerUp SYBR Green (Applied Biosystems) using
1.5 µl cDNA per replicate and 400 nM primers (Table S1, IDT). In both
cases, PCR amplificationwas carried out in theApplied Biosystems StepOne
Plus thermocycler, using cycling parameters recommended by Qiagen
(miRNA) and Applied Biosystems (mRNA). Data were acquired with
Applied Biosystems SDS2.3 software. Passive reference dye ROX (Thermo
Fisher Scientific) was included in all reactions. Expression datawere analysed
by relative quantification using the comparative Ct method (2−ΔΔCt). miR-
26a-5p levels were analysed as relative expression to 4 h, using the geometric
mean ofmiR-100-5p, miR-128-3p,miR-134-5p,miR-434-3p and let7a-5p as
a reference. miRNA reference genes were selected according to two
parameters: detectable expression by RT-qPCR in axonal RNA samples;
and stable expression in previous in-house RT-qPCR studies on the
development of cortical neuronal cultures. All of the selected miRNA
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reference genes changed less than 1 Ct (n≥3) over 12 days in culture
(Table S2). In studies of dissociated cortical cultures, Gsk3b levels were
analysed as relative expression to 4 h, where the geometric mean of Gapdh
and Ube2 levels was used as reference. All data are expressed as fold change
to 4 h±s.e.m. RT-qPCR experiments in the axonal fractions of cortical
primary microfluidic cultures showed detectable levels of miR-26a and
GSK3β in cortical axons (miR-26a average Ct=29.95±0.05; GSK3β average
Ct=26.92±0.30; n=3 independent experiments). miR-26a levels in the axons
were within the range of detection for mature miRNAs and comparable with
previous miRNA qPCR quantification experiments in cortical and DRG
axons (Natera-Naranjo et al., 2010; Zhang et al., 2013).
Immunofluorescence
Cortical neurons cultured on coverslips or microfluidic devices were fixed
using 4% paraformaldehyde (w/v) (Thermo Fisher Scientific) for 30 min,
washed with 10 mM glycine in PBS, permeabilised in PBS/glycine-Triton
(1× PBS, 10 mM Glycine, 0.2% Triton X-100; Sigma-Aldrich), blocked
with 3% bovine serum albumin in PBS (BSA; Sigma-Aldrich) and further
incubated with the appropriate primary antibodies overnight (Table S1).
Following PBS-Triton 0.1% washes, cells were incubated with secondary
antibodies (Alexa Fluor 488 and 568; 1:300Molecular Probes) andmounted
with Vectashield Hardset mounting media with Dapi (Vectorlabs).
Data analysis
Measurement of axons in dissociated cortical cultures
For quantification of axon length, an axon was defined as a neurite that was
at least three times the length of any other neurite and measured from the
soma to the distal extent of the central region of the growth cone using Fiji
software (Dajas-Bailador et al., 2008; Schindelin et al., 2012). Data are
expressed as mean percentages of respective controls (∼300 axons measured
for each condition from four to six independent experiments)±s.e.m. In
GSKβ-TSB experiments, cultures were immunostained for βIII-tubulin and
∼100 neurons from ∼40 random fields were analysed per condition per
experiment (∼400 axons from four independent experiments). The average
length of axons in control groups was 115±1.96 μm (mean±s.e.m.).
Measurement of neurites and developing dendrites length
In experiments where neurons were transfected with 20 nM of miR-26a
mimic, neurite length was assessed by measuring the length from the soma
to the distal tip of all the projections in each GFP-positive cell. In miR-26a
inhibitor transfection experiments (50 nM), all neurites of non-polar
neurons and developing dendrites of single-axon (polarised) neurons were
measured following the same protocol. Data are expressed as mean
percentages of respective controls (∼700 projections measured for each
condition from four independent experiments)±s.e.m.
Polarity assessment
The aforementioned criteria for the definition of axon was also used to
define a neuron as a polarised cell. Neuronal polarisation in culture was then
assessed by determining the fraction of polarised cells with respect to
the total number GFP-positive cells. The dataset of five independent
experiments was normalised and expressed as percentage of control (mean
±s.e.m.). Multi-polar neurons were identified as neurons bearing more than
one axon, defined as a neurite with JIP1-positive tips (Dajas-Bailador et al.,
2014, 2008; Deng et al., 2014; Fu and Holzbaur, 2013). The data set of five
individual experiments was normalised to respective control and expressed
as percentage of control (mean±s.e.m.).
Quantification of fluorescence signal
Neurons labelled for GSK3β were imaged at 63× and images were further
processed with Fiji software. Somas and growth cones were manually
selected and the area, mean grey value and integrated density were
measured. In order to correct for background in each image, three empty
areas were selected around every soma/growth cone. Total cell fluorescence
(C.F.) per cell was calculated as the measured integrated density corrected
for background, according to the formula: C.F.=Integ.Density−[Area of
soma×Average (mean grey value of background)]. For quantification of
endogenous GSK3β in culture, ∼200 somas and 100 growth cones were
measured in each condition from at least four independent experiments. Data
were normalised to the average C.F. of the control expressed in percentage
as mean±s.e.m. To control for imaging artefacts, neurons labelled for
βIII-tubulin were imaged following the same protocol in both neuronal
somas and growth cones (Fig. S7).
Measurement of axon length in microfluidic cortical cultures
The length of the axons was measured using Fiji software by tracing at least
125 axons in each condition from five independent experiments; each axon
was traced from the edge of microgrooves to the growth cone of the longest
axonal branch. In all the experiments, data for the different timepoints in
each chamber was normalised to t0 and expressed as a percentage of
respective controls (mean±s.e.m.).
Quantification of fluorescence signal in microfluidic cortical culture and
after disruption of axonal transport
For quantification of endogenous GSK3β levels, ∼200 somas and ∼200
growth cones were measured in each condition from at least five
independent experiments. Data were normalised to the average C.F. of the
control expressed in percent as mean±s.e.m.
Statistical analysis
In all statistical tests, n refers to the number of independent experimental
repeats, which varied from four to eight depending on experimental model
(see specific section for details). Data analysis was carried out using Prism
v7.0 (GraphPad Software) and all data groups shown are expressed as mean
±s.e.m. For sample sizes of n<5, individual data points are also shown in
graphs. The probability distribution of the data set was analysed before
further statistical analysis (Shapiro–Wilk test). Statistical evaluation
between two groups was performed using unpaired Student’s t-test.
Analyses of more than two groups were carried out using one-way
ANOVA with Bonferroni post-hoc analysis. Kruskal–Wallis’ test followed
by a Dunn’s multiple comparisons test was used for non-parametric
distributions. For all tests, P<0.05 was used as threshold for significant
difference. For all tests, P values are two-tailed.
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